Name PRICE MARKET CAPITALIZATION PRICE TO EARNINGS RATIO DIVIDEND YIELD SYMBOL EXCHANGE PRICE PERCENT DIFFERENCE YEAR TO DATE PRICE PERCENT DIFFERENCE 5 YEAR CHART 1 YEAR CHART

ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases.

http://www.contrafect.com


CFRX $0.44 -0.02 (-4.35%)
Sector Health Care
Industry Biotech & Pharma
Market Cap 30 Million
EPS 0.07 P/E Ratio 0.00
Previous Earnings Thu, Aug 9, 2018
Latest Earnings Thu, Nov 8, 2018
Dividend --
Ex-Date --
Dividend Pay Date --
Dividend History --

0.44 0.03 0.00 0.00 CFRX NASDAQ -4.35 -75.28 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CFRX&exchange=NASDAQ&chart=5 https://www.symbolsurfing.com/charts/stock_price_chart.php?user_id=true&symbol=CFRX&exchange=NASDAQ&chart=1

Symbol Surfing has been referenced on Barrons, CNN & Investor Place.

About | Blog | Advertising | Terms | info@symbolsurfing.com

Investing Quotes #Legendary


Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Some links on this website are advertisements and/or affiliate links and Symbol Surfing receives compensation.

©2019 Symbol Surfing All Rights Reserved. Privacy Policy | ^Top